Global Market Study on Hemoglobinopathy: Europe Estimated to be the Dominant Regional Market in 2016


Hemoglobinopathy Market
  • Published On : Oct-2016 |
  • Pages : 131 Pages |
  • Format :

This report by Persistence Market Research examines the global hemoglobinopathy market for the period 2016–2024. The primary objective of the report is to offer updates and information related to market opportunities in the global hemoglobinopathy market. The global hemoglobinopathy market report begins with an exhaustive executive summary giving the report data overview and the market taxonomy or segments covered in the report. It is followed by an overview of market dynamics of the global hemoglobinopathy market, which includes an in-depth analysis of key trends, drivers, restraints, and opportunities, and reimbursement scenario influencing the growth of the global hemoglobinopathy market. Impact analysis of key growth drivers and restraints based on a weighted average model have been included in the report after detailed analysis of individual regions to better equip readers with meaningful insights on ongoing developments in the global hemoglobinopathy market.

Based on indication type, the market has been segmented into Sickle Cell Disease, Beta Thalassemia, and Alpha Thalassemia. A detailed analysis has been provided for these segment in terms of market size, Y-o-Y growth rate, absolute $ opportunity, and BPS analysis. Based on test type, the market has been segmented into red blood cell (RBC) count test, genetic testing, hemoglobin by high performance liquid chromatography (HPLC) test,  hemoglobin isoelectric (Hb IEF) focusing, hemoglobin electrophoresis (Hb ELP) test, and hemoglobin solubility test. The next section of the report analyzes the global hemoglobinopathy market by region and provides a comprehensive market outlook for 2016–2024. The report also analyzes the impact of drivers and restraints in each region. Key regions assessed in this report include North America, Latin America, Europe, Asia Pacific (APAC), and Middle East & Africa (MEA). These sections evaluate the present scenario and future growth prospects of the global hemoglobinopathy market during the period 2016–2024. We have considered 2015 as the base year and provided data for the forecast period, i.e., 2016–2024.

In the final section of the report on the global hemoglobinopathy market, a competitive landscape is included to provide report audiences with a dashboard view based on categories of providers in the global hemoglobinopathy market product portfolio and key differentiators. Key categories of providers covered in the report are hemoglobinopathy diagnosis devices, ready-to-use kits, and reagents manufacturers. This section is primarily designed to provide clients with an objective and detailed comparative assessment of key providers specific to a market segment in the global hemoglobinopathy market value chain. Report audiences can gain segment-specific vendor insights to identify and evaluate key competitors based on an in-depth assessment of their capabilities and successes in the global hemoglobinopathy market. Detailed profiles of providers are also included in the scope of the report to evaluate their long- and short-term strategies, key offerings, SWOT analysis, and recent developments in the global hemoglobinopathy market. Key competitors covered in terms of manufacturers include Abbott Diagnostics, Bio-Rad Laboratories Inc., Danaher Corporation, Mindray Medical International Ltd., Nexcelom Bioscience LLC., Nihon Kohden Corporation, PerkinElmer Inc., Siemens Healthineers, and Sysmex Corporation. 

Research methodology

To ascertain the global hemoglobinopathy market size, we have considered revenue generated by device manufacturers. The forecast presented here assesses the total revenue by value across the global hemoglobinopathy market. In order to offer an accurate forecast, we started by sizing up the current market, which forms the basis of how the global hemoglobinopathy market is expected to develop in the future. Given the characteristics of the market, we have triangulated the outcome of three different types of analyses based on supply side, downstream industry demand, and the economic envelope. In addition, it is imperative to note that in an ever-fluctuating global economy, we not only conduct forecasts in terms of CAGR, but also analyze it based on key parameters such as year-on-year (Y-o-Y) growth rates to understand the predictability of the market and to identify the right opportunities across the global hemoglobinopathy market.

The different segments of the global hemoglobinopathy market are analyzed in terms of Basis Point Share (BPS) to understand individual segments’ relative contribution to market growth. This detailed level of information is important for identifying various key trends in the global hemoglobinopathy market. Another important feature of this report is the analysis of key segments in terms of absolute dollar opportunity, critical for assessing the level of opportunity that a provider can look to achieve, as well as to identify potential resources from a sales and delivery perspective in the global hemoglobinopathy market. To understand key growth segments in terms of growth and adoption for hemoglobinopathy diagnosis globally, Persistence Market Research has developed the global hemoglobinopathy market attractiveness index to help providers identify real market opportunities.

Hemoglobinopathies are a diverse set of congenital blood ailments that are a consequence of disparities in the structure and/or synthesis of hemoglobin. Hemoglobinopathies are genetic single-gene disorders that lead to an abnormal structure of one of the globin chains of the hemoglobin molecule, rendering it unable to carry oxygen through the body, which leads to anemia or other medical abnormalities. The most common hemoglobinopathies are sickle cell disease, alpha thalassemia, and beta thalassemia. The global hemoglobinopathy market is projected to register a CAGR of 8.3% during the forecast period in terms of value and is expected to reach a market valuation of US$ 788.2 Mn by the end of 2024.

Market dynamics

Growth of the global hemoglobinopathy market is mainly driven by a growing prevalence of hemoglobinopathies in developed nations, high disease occurrence in underdeveloped nations, various supportive government initiatives, and non-government organizational funding. Other factors driving the global hemoglobinopathy market are advanced diagnostics and therapeutics, favorable reimbursement scenario for diagnostic tests and treatment, cost-effective preventive approach like genetic testing, and development of rapid point-of-care diagnostic methods.

However, lack of awareness regarding hemoglobinopathy disorders amongst the population especially in underdeveloped countries and lack of high sensitivity and specific diagnostic tests are expected to restrain growth of the market over the forecast period. Focus on novel diagnostic approaches and development of fast, reliable, and cost-effective diagnostic methods will define the future landscape of the global hemoglobinopathy market.

Segment analysis

The global hemoglobinopathy market has been segmented on the basis of indication, test type, end users, and region. Based on indication type, the market has been segmented into sickle cell disease, alpha thalassemia, and beta thalassemia. Sickle cell disease segment is expected to be the most lucrative segment in the global hemoglobinopathy market owing to increasing incidences of sickle cell disease. In terms of value, sickle cell disease segment is estimated to account for 52.4% share of the global hemoglobinopathy market by 2016 end.

Based on major end users, the global hemoglobinopathy market is segmented into hospitals, diagnostic laboratories, and clinics. Diagnostic laboratories followed by hospitals are expected to account for the highest share of the global hemoglobinopathy market over the forecast period. In terms of value, diagnostic laboratories segment is estimated to account for the highest market share of 49.4% of the global hemoglobinopathy market by 2016 end.

Based on the test types, the market has been segmented into red blood cell (RBC) count test, genetic testing, hemoglobin by high performance liquid chromatography (HPLC) test, hemoglobin isoelectric (Hb IEF) focusing, hemoglobin electrophoresis (Hb ELP) test, and hemoglobin solubility test. Red blood cells (RBC) count test segment currently accounts for the highest revenue of the global hemoglobinopathy market owing to the fact that it is a basic test performed prior to most hemoglobinopathy diagnosis tests. In terms of value, routine red blood cell (RBC) count segment is estimated to account for the highest market share of 30.4% by 2016 end.

hemoglobinopathy market

Regional analysis

The global hemoglobinopathy market has been segmented into five major regions: North America, Latin America, Europe, Asia Pacific (APAC), and Middle East & Africa (MEA). In terms of value, Europe is estimated to be the dominant regional market in the global hemoglobinopathy market in 2016 owing to a robust healthcare infrastructure and high prevalence of thalassemia in Mediterranean countries like Cyprus and Greece. The Europe hemoglobinopathy market is expected to register a CAGR of 7.9% over the forecast period. Asia Pacific and Middle East & Africa are estimated to be the fastest growing markets in terms of CAGR. The North America hemoglobinopathy market is expected to register a CAGR of 7.6% over the forecast period.

Key market players

Some key players in the global hemoglobinopathy market are Abbott Diagnostics, Bio-Rad Laboratories Inc., Danaher Corporation, Mindray Medical International Ltd., Nexcelom Bioscience LLC., Nihon Kohden Corporation, PerkinElmer Inc., Siemens Healthineers, and Sysmex Corporation. Manufacturers are focused on manufacturing cost-effective and rapid diagnostic methods. Furthermore, companies operating in the global hemoglobinopathy market are focusing on the development of novel point-of-care diagnostic tests.

Company Profiles 

  • Abbott Diagnostics
  • Bio-Rad Laboratories, Inc.
  • Danaher Corp.
  • Mindray Medical International Ltd
  • Nexcelom Bioscience LLC.
  • Nihon Kohden Europe Ltd
  • PerkinElmer Inc.
  • Siemens Healthineers
  • Sysmex Europe GmbH
  • Others
Back To Top